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Abstract
Background:  Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasm of the
gastrointestinal (GI) tract which has only been recently described based on their specific immunohistochemistry and the
presence of particular KIT-related mutations which potentially make them targets for tyrosine kinase inhibition.
Methods: Sixty-one patients (29 M; 32 F, median age 60 years; range: 23–86 years) between June 1994 and March 2005,
were analyzed from two allied institutions. Patient, tumour, and treatment variables were analyzed to identify factors
affecting survival.
Results: Of the 61 patients, 55 (90%) underwent complete surgical resection of macroscopic disease. The 5-year overall
survival (OS) rate in the 61 patients was 88% and the 5-year disease-free survival (DFS) in the 55 cases completely
resected was 75%. Univariate analysis revealed that R0 resection was strongly associated with a better OSrate (p <
0.0001). Likewise, univariate analysis also showed high mitotic count of > 10 mitoses/per 50 HPF was a significant variable
in worse prognosis for OS (≤ 10 mitoses/per 50 HPF 95% 5-year OS vs. > 10 mitoses/per 50 HPF 74% 5-year OS,
respectively; p = 0.013). On subsequent multivariate analysis, only high mitotic count remained as a significant negative
prognostic variable for OS (p = 0.029). Among patients resected for cure, there were 8 recurrences during follow-up.
The mean time to recurrence was 21 ± 10 months (range: 4–36 months). Univariate analysis revealed that mitotic count
of > 10 mitoses per 50 high power fields, intratumoural necrosis, and pathological tumour size (> 10 cm in maximal
diameter) significantly correlated with DFS (p = 0.006, 0.002 and 0.02, respectively), with tumour necrosis and high
mitotic count remaining as independent predictive variables affecting prognosis on subsequent multivariate analysis.
Conclusion: Most GISTs are resectable with survival principally dependent upon mitotic count and completeness of
resection. Future metabolic and genetic analyses will define the role of and resistance to induction or postoperative
adjuvant targeted kinase inhibition therapy.
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Background
Gastrointestinal stromal tumors (GISTs) are uncommon
tumours which have relatively recently been separated
from conventional leiomyomas, leiomyoblastomas, and
leiomyosarcomas, based on their specific immunohisto-
chemistry, presumed aetiopathogenesis, molecular biol-
ogy and differential outcome [1,2]. There is still
controversy over their histogenetic origin with immuno-
histochemical and ultrastructural resemblance to the
interstitial cells of Cajal [3,4] as well as from cells which
are smooth muscle cell precursors responsible for genera-
tion of the slow-wave pacemaker activity of the gut mus-
culature [5]. The designation of these tumours has largely
been based on the immunohistochemical expression of c-
KIT (CD 117; stem cell factor [6,7], and CD 34) [8], with
a relative lack of desmin and S-100 immunoreactivity,
although recently, a subset of KIT-negative GISTs has been
recognised with the morphological features of classical
stromal tumours but retaining PKC-theta expression [9].
More recently, cytogenetic and comparative genomic
hybridisation (CGH) studies have shown characteristic
chromosomal patterns in GISTs which have distinguished
them from other gastrointestinal mesenchymal tumours,
[10] and where most GISTs demonstrate specific DNA
copy number changes which correlate with their clinical
behaviour and which differentiate benign from malignant
cases [11].
Considerable debate still exists concerning the biological
behaviour of GISTs, centering largely around the tumour
site, tumour size, the presence of intra-tumoural necrosis,
and mitotic count [12-14]. Based on this recent data, our
study assesses the surgical outcome of unselected GISTs
referred to two allied institutions over a 10 year period
and analyses the factors affecting prognosis after resection
with curative intent.
Patients and methods
Patients
Using our hospital databases, we collected the records of
patients with a histopathologic diagnosis of primary leio-
myoma, leiomyoblastoma, leiomyosarcoma, gastrointes-
tinal sarcoma, and stromal cell tumour of the GI tract
from the period including 1994 to October 2004. Each of
the patients had undergone surgical resection of their
tumour. We recorded the patients' age, gender, presenting
clinical symptoms, tumour site, maximal tumour diame-
ter after resection, duration of surgery, surgical procedure,
extent of surgical resection, the presence and date of local
recurrence or distant metastasis, and the clinical outcome
until last follow-up, including date of death where appro-
priate. There was no strict follow-up protocol in either
institution, although follow-up included physical exami-
nation, chest X-ray, thoracoabdominal and pelvic compu-
terised tomography (CT) scan, endoluminal
ultrasonography, and GI endoscopy, where appropriate.
The median follow-up of all patients was 35 months
(range 2–140 months). Those tumours deemed to have
histologically free resection margins were included as
cases where surgery was performed with curative intent
and were referred to as complete (R0) resections. After the
surgical treatment, patients were followed regularly using
clinical assessment on a 3 monthly basis with abdomi-
nopelvic CT and/or ultrasound annually, where appropri-
ate.
Immunohistochemistry
The tumour samples from all 61 patients were evaluated
for various markers by using immunohistochemistry with
commercially available antibodies against CD 117-KIT,
(1:50, Santa Cruz Biotech, CA USA) S-100 protein, (1:40,
Novocastra Labs, USA) Desmin, (1:50, DAKO, Glostrup,
Denmark) and Smooth-muscle Actin (1:200, DAKO,
Glostrup, Denmark) with qualitative assessment of
immunoreactivity in accordance with the manufacturers'
instructions. Cases were classified according to risk and
their potential for aggressive clinical behaviour based on
the NIH consensus statement of 2001 for GISTs, [15]
where tumour size < 2 cm and mitotic count < 5/50 high
power fields (HPF) was graded as very low risk, tumour
size between 2 and 5 cm and a mitotic count < 5/50 HPF
was considered low risk, tumours < 5 cm with a mitotic
count between 5/50 HPF and 10/50 HPF or tumours
between 5 and 10 cm with a mitotic count less than 5/50
HPF were deemed as intermediate risk and tumours > 10
cm and/or those tumours with a mitotic count > 10/50
HPF and tumours > 5 cm with a mitotic count > 5/50 HPF
were classified as high risk.
Statistics
Statistical analysis was performed with SPSS 12.0 software
(Chicago, IL, USA). The Student's t test was used to com-
pare continuous variables with the χ2 test being utilized
for dichotomous variables. Overall survival was calculated
from the day of diagnosis until death or the last day of a
patient's visit to the outpatient clinic. The disease-free sur-
vival was calculated from the first diagnosis until tumour
recurrence or distant metastases were found. Kaplan-
Meier analysis with a Mantel-Haenszel log-rank test was
used to compare overall and recurrence-free survival [16]
with the proportional hazards method being used to eval-
uate significant prognostic factors [17]. All p values < 0.05
are reported.
Results
Of the resected cases, there were 29 males and 32 females
with an overall median age 60 years (range 23–86 years).
All tissue samples were proven to be CD-117 positive on
immunohistochemical staining. Tumours were located in
the stomach in 41 cases (67%), the small bowel in 14World Journal of Surgical Oncology 2006, 4:73 http://www.wjso.com/content/4/1/73
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(23%), the colon in 4 (5%) the rectum in 1 (2%), and the
duodenum in 2 cases (3%). Three of the 61 patients (5%)
presented with synchronous hepatic metastases. The most
frequent presenting symptoms included gastrointestinal
tract bleeding and abdominal pain in 11 cases (18%) and
abdominal fullness and/or discomfort in 7 patients
(11%). Twenty patients (33%) had anaemia on presenta-
tion with 15 patients (26%) having a palpable abdominal
mass on clinical examination. Six patients (10%) were
asymptomatic and were referred for incidental GISTs after
routine physical examination and investigation.
The surgeries performed for the patient cohort are shown
in Table 1. One patient with a gastric GISTs and a single
synchronous hepatic metastasis in segment III underwent
a non-anatomical wedge resection of the liver at the same
time as their gastric resection. Postoperative complica-
tions included gastrointestinal hemorrhage in one case,
duodenal leakage in a further patient, and urosepsis in
one case. Perioperative 30 day mortality was 0 per cent.
Pathological assessment of the resected tumours showed
a median tumour size of 5.3 cm (range, 0.6–38 cm). Ten
tumours (16%) were < 2 cm in maximal diameter, 19
(31%) between 2–5 cm, 17 (28%) between 5–10 cm and
15 (25%) > 10 cm. The mitotic counts were < 5/50 per
HPF in 37 cases (61%), between 5 and 10/50 per HPF in
a further 6 (10%) and > 10/50 per HPF in 18 (29%) cases.
Ulceration of the tumour was noted in 69% (42/61),
haemorrhage in 25% (15/61), and tumour necrosis in
28% (17/61). Six patients (10%) underwent palliative
surgery because of tumour bleeding resulting in severe
anaemia, 3 patients presented with synchronous resecta-
ble hepatic metastases, and a further 3 presented with an
unresectable intra-abdominal tumour. According to the
NIH Consensus Conference criteria, of all cases there were
10 patients (16%) in the very low risk class, 15 cases
(25%) in the low risk class, 7 (11%) in the intermediate
risk class, and 29 (48%) in the high risk class. Table 2
shows the clinico-pathological data of patients according
to the number of mitoses per HPF (i.e. ≤ or > 10/50).
Of the 61 patients resected, 55 (90%) had their tumour
completely resected as an R0 resection as described in the
methods section. The 5-year overall survival rate for these
patients was 88%, compared with 0% (0/6) for those
patients who underwent palliative surgery (p < 0.0001).
During the follow-up period, 5 patients died of recurrent
disease, all of whom were in NIH class 4 on initial presen-
tation. A further 2 patients died of myocardial infarction
during the follow-up period but were free of tumour at the
time of their deaths. Seven patients who experienced
recurrence were treated with Imatinib 400 mg daily and 6
of them are still alive after a median follow-up period of
18 months. Figure 1 shows the overall and disease-free
survival of all GISTs in the series undergoing all types of
resections. On univariate analysis, histological resection-
free margins (i.e., R0 resection margins) were strongly
associated with improved overall survival (91% 5-year
overall survival for complete resection vs. 0% for incom-
plete resections, p < 0.0001). This effect was preserved in
patients presenting with advanced classes of disease,
where amongst the NIH class 4 patients completeness of
resection correlated with overall survival (83% 5-year
overall survival for complete resection vs. 0% 5-year over-
all survival for incomplete resection, p = 0.0031). The
other significant factor affecting overall survival on uni-
variate analysis was the number of mitoses (> 10 per 50
HPF) where there was a 95% 5-year overall survival for
patients with a mitotic count ≤ 10 per 50 HPF vs. 74% 5-
year overall survival for patients with a mitotic count > 10
per 50 HPF, p = 0.013) (Figure 2). Multivariate analysis of
these two significant factors detected on univariate analy-
sis revealed that the number of mitoses (> 10 per 50 HPF)
was the only significant independent predictive variable
affecting overall survival (HR = 12.350; CI 1.295–
117.781: p = 0.029).
The 5-year disease-free survival in the 55 patients com-
pletely resected was 75% (Figure 2). Among those patients
resected for cure, 8 patients developed tumour recurrence
after a mean of 21 ± 10 months (range: 4–36 months) fol-
low-up. The liver was the most frequent site of tumour
relapse (n = 6; 75% of the recurrences) and in the 8
Table 1: Surgical procedures performed in 61 patients affected by gastrointestinal stromal tumours.
Surgical procedure N (%)
Wedge gastric resection* 31 (51)
Small bowel resection 14 (23)
Subtotal gastrectomy 8 (13)
Colonic resection 3 (5)
Total gastrectomy 2 (3)
Duodenum-pancreatectomy 2 (3)
Transanal excision 1 (2)
*One patient underwent non-anatomical wedge liver resection at the same time as the gastric resection for an isolated liver metastasis in segment 
III.World Journal of Surgical Oncology 2006, 4:73 http://www.wjso.com/content/4/1/73
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patients, survival after recurrence was 30% at 3 years.
Patients designated as NIH class 4 had a 5-year disease-
free survival rate of 65% compared with 94% for all other
groups combined (p = 0.03). On univariate analysis, a
higher number of mitoses (i.e. > 10 per 50 HPF) corre-
lated with worse disease free-survival in those resected for
cure (87% for < 10 mitoses/per 50 HPF vs. 57% for > 10
mitoses/per 50 HPF respectively, p = 0.006), as did
tumour size (tumours < 10 cm in maximal diameter had
an 86% disease-free survival at 5 years compared with
only 63% for those tumours > 10 cm in size; p = 0.02).
The presence of tumour necrosis was also significantly
associated with a worse disease-free survival on univariate
analysis (51% vs. 91% 5-year disease-free survival with or
without tumour necrosis respectively; p = 0.002). On mul-
tivariate analysis of these three significant factors detected
on univariate analysis, only tumour necrosis and the
number of mitoses (> 10 mitoses/per 50 HPF) proved to
be significant independent predictive variable affecting
disease-free survival (HR = 11.226; CI 2.199–57.315: p =
0.004 and HR = 8.054; CI 1.842–35.205: p = 0.006,
respectively).
Discussion
Analysis of 61 cases of mixed-site GISTs in our study
obtained from two tertiary referral centres over a 10-year
period reveals that both overall survival and disease-free
survival are affected by a high mitotic count in the tumour
after resection with curative intent. The primary tumour
sites noted in our study are similar to other previous
reports [18,19], with a similar demographic of presenting
symptoms including gastrointestinal bleeding, abdomi-
nal pain and the presence of an abdominal mass [20-22].
CT and MRI are generally used for the preoperative imag-
ing of GISTs [23-25]. However, there are no well-estab-
lished, published guidelines to help surgeons determine
the optimal manner in which to evaluate this intraabdom-
inal, site-specific class of tumours. Although not reported
in the results section of our current report, our limited use
of endoluminal ultrasound has been unable to assist in
the definition of malignant versus benign cases. Neverthe-
less, this has been as previously described [26], where
tumour margin irregularity and heterogeneity with intra-
tumoural degeneration and larger tumour size were more
indicative of malignancy. No patient in our series under-
went preoperative image-guided biopsy or aspiration
cytology as has been advocated by some authors [27].
Lastly, recent data shows a potential value for preopera-
tive positron emission tomography (PET) in the predic-
tion of malignant potential with a correlation between
18FDG uptake and mitotic count [28]
Others have shown that one of the principal prognostic
factors determining cancer-specific outcome is tumour
size, where tumours > 10 cm in maximal diameter have a
relatively worse survival following surgical resection
[2,12,18]. Our study was unable to substantiate an effect
of tumour size except on univariate analysis of overall sur-
vival. This effect was not mantained on multivariate anal-
ysis, although larger patient numbers are probably
required to determine a true effect of tumour size on can-
cer-specific outcomes. In this respect, GISTs, which exceed
5 cm in maximal diameter, have been previously shown
to correlate with a worse prognosis independent of their
Table 2: Clinico-pathological variables of 61 gastrointestinal stromal tumours patients according to number of mitoses per 50 HPF(≤ 
or > 10)*
Mitoses ≤ 10/50 per HPF Mitoses > 10/50 per HPF p
Tumour location 0.09
stomach 28 (68)§ 13 (32)
colon-rectum 1 (25) 3 (75)
small bowel 12 (86) 2 (14)
duodenum 2 (100) 0
Surgical resection type 0.04
R0 42 (74) 15 (26)
R1+R2 1 (25) 3 (75)
Tumour diameter 0.71
≤ 10 cm 33 (72) 13 (28)
> 10 cm 10 (67) 5 (33)
Tumour necrosis
absent 33 (75) 11 (25)
present 10 (59) 7 (41) 0.21
*HPF, high power field
§Numbers in parentheses are percentages.World Journal of Surgical Oncology 2006, 4:73 http://www.wjso.com/content/4/1/73
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primary location, [19,29] where tumour diameter is part
of most prognostic indices designed to govern treatment
algorithms for patients deemed at high risk [2,15,30].
Equally, as in our study, most reports have shown high
mitotic count to equate with a worse tumour-specific out-
come [12,31], although some recent studies have
excluded this factor along with that of intratumoural
necrosis from model analyses since they have not been
proven to be independent prognostic markers of survival
[12,32]. Our study showed an effect of intratumoural
necrosis on disease-free but not overall survival. Other
studies have confirmed more objective immunohisto-
chemical evaluation of cellular proliferation as correlating
with an overall worse outcome using Ki 67 analysis, [2]
proliferating cell nuclear antigen labelling index, cellular
apoptotic marker (Bcl-2 and Bax) expression and overall
tumour cellularity estimates [12,33,34].
The clinicopathologic evaluation of GISTs is particularly
difficult, since these tumours have only recently been
characterized and since some previous studies have still
grouped these tumours with spindle-cell and epithelial
neoplasms, which may share similar histopathology, but
which possess divergent outcomes. Attempts have been
made to categorize these tumours by the establishment of
an individualized immunophenotype based on neural
and smooth muscle immunodifferentiation although up
to one-quarter of these neoplasms cannot adequately be
categorized on this basis [35]. No patient in our series was
treated primarily with the tyrosine kinase inhibitor Imat-
inib, which has been shown to be valuable in metastatic
kit-positive GISTs [36,37]. We have used this in our units
only after proven disease recurrence. This issue is com-
plex, since although most GISTs acquire a gain-of-func-
tion c-KIT mutation, many tumours ultimately
Overall survival and disease-free survival in 61 patients with GIST tumours Figure 1
Overall survival and disease-free survival in 61 patients with GIST tumours.
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demonstrate some resistance to targeted molecular ther-
apy during treatment [38]. It appears that c-KIT gene
mutations are pivotal molecular events in the life of these
tumours, adversely affecting their overall prognosis after
surgery [39]. Equally, there is controversy regarding the
mechanisms of Imatinib resistance which are dependent
upon missense mutations of the kinase domains of KIT
and PDGFRA and there is no clear evidence at the present
time that routine molecular analysis of GISTs to assess
exon mutations alters management [40]. Moreover, the
follow-up protocol for resected GISTs has not been estab-
lished although there are relatively specific changes
detectable in tumours treated primarily with Imatinib on
CT and MR imaging, including changes in tumour size,
attenuation, enhancement, and vascularity [41,42]
Conclusion
Our and other studies suggest that complete surgical resec-
tion (R0 resection) of GISTs as well as their initial size,
mitotic activity, and the presence of intratumoural necro-
Overall survival according to number of mitoses for the 61 patients with GIST tumours Figure 2
Overall survival according to number of mitoses for the 61 patients with GIST tumours.
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sis are potentially important variables associated with
overall outcome, with the principal factor affecting overall
survival being the mitotic count. These findings have been
suggested in another very recently published report [43].
In the era of Imatinib effectiveness, it is unclear what is the
role of preoperative induction or postoperative adjuvant
targeted therapy, as well as the place of surgery in partial
Imatinib responsiveness or in isolated metastatic disease
[44]. In this light, at the present time, it may be that a clin-
ico-pathological interpretation of the risk status of the
tumour, as used in our study, is the most practical
approach for such decision where complete surgical resec-
tion (R0 resection) is the key prognostic factor [45] and
where high-risk GISTs surgery is supported by a selective
approach towards induction or postoperative adjuvant
molecular therapy [46,47].
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